1.Harper JW,Adams PD.Cyclin-dependent kinases.Chem Rev.2001 Aug;101(8):2511-2526.
2. Morgan DO. Principles of CDK regulation. Nature. 1995 Mar 9;374(6518):131-134.
3.Dyson N.The regulation ofE2F by pRB-family proteins.Genes Dev.
1998Aug1;12(15):2245-2262.
4.Weinberg RA.The retinoblastoma protein and cellcycle control.Cell. 1995May5;81(3):323-330.
5.Chen YN,Sharma SK,Ramsey TM,Jiang L,Martin MS,BakerK, Adams PD,BairKW,Kaelin WG Jr.Selective killing oftransformed cells by cyclin/cyclin-dependentkinase 2 antagonists.Proc NatlAcad SciU S A.1999Apr13;96(8):4325-4329.
6. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpointcontrol. JClinInvest.1999Dec;104(12):1645-1653.
7. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinasesincellcyclecontrol.Science.1993Dec24;262(5142):2050-2054. 8. Loyer P, Trembley JH, Katona R, Kidd VJ, Lahti JM. Role of
CDK/cyclin complexes in transcription and RNA splicing.CellSignal. 2005Sep;17(9):1033-1051.
9.Zhao J,Kennedy BK,Lawrence BD,Barbie DA,Matera AG,Fletcher JA, Harlow E. NPAT links cyclin E-Cdk2 to the regulation of replication-dependenthistone gene transcription.Genes Dev.2000 Sep 15;14(18):2283-2297.
10.Malumbres M,Barbacid M.To cycle or not to cycle: a critical decisionincancer.NatRevCancer.2001Dec;1(3):222-231.
11.PorterPL,MaloneKE,Heagerty PJ,AlexanderGM,GattiLA,Firpo EJ,DalingJR,RobertsJM.Expressionofcell-cycleregulatorsp27Kip1 and cyclin E,alone and in combination,correlate with survivalin youngbreastcancerpatients.NatMed.1997Feb;3(2):222-225.
12.SchramlP,BucherC,BissigH,NocitoA,HaasP,WilberK,SeeligS, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G. Cyclin E overexpression and amplification in human tumours.J Pathol.2003 Jul;200(3):375-382.
13.Soria JC,Jang SJ,KhuriFR,Hassan K,Liu D,Hong WK,Mao L.
Overexpression ofcyclin B1in early-stagenon-smallcelllung cancer anditsclinicalimplication.CancerRes.2000Aug1;60(15):4000-4004.
14.TakenoS,NoguchiT,KikuchiR,UchidaY,YokoyamaS,MüllerW.
Prognostic value ofcyclin B1 in patients with esophagealsquamous cellcarcinoma.Cancer.2002Jun1;94(11):2874-2881.
15.CaiD,Latham VM Jr,Zhang X,Shapiro GI.Combined depletion of cellcycleandtranscriptionalcyclin-dependentkinaseactivitiesinduces apoptosisincancercells.CancerRes.2006Sep15;66(18):9270-9280. 16.Tetsu O,McCormick F.Proliferation ofcancer cells despite CDK2
inhibition.CancerCell.2003Mar;3(3):233-245.
17.FiettaP.Many waystodie:passiveand activecelldeath styles.Riv Biol.2006Jan-Apr;99(1):69-83.
18. Lorenzo HK, Susin SA. Therapeutic potential of AIF-mediated caspase-independentprogrammed celldeath.Drug ResistUpdat.2007
Dec;10(6):235-255.
19.Koh DW,Dawson TM,Dawson VL.Mediation of cell death by poly(ADP-ribose)polymerase-1.PharmacolRes.2005Jul;52(1):5-14. 20.Nieminen AL,GoresGJ,Wray BE,Tanaka Y,Herman B,Lemasters
JJ. Calcium dependence of bleb formation and cell death in hepatocytes.CellCalcium.1988Dec;9(5-6):237-246.
21.Herman B,Nieminen AL,Gores GJ,Lemasters JJ.Irreversible injury in anoxic hepatocytes precipitated by an abruptincrease in plasma membranepermeability.FASEB J.1988Feb;2(2):146-151.
22.DeAzevedoWF,LeclercS,MeijerL,HavlicekL,StrnadM,Kim SH.
Inhibition of cyclin-dependent kinases by purine analogues:crystal structureofhuman cdk2 complexed with roscovitine.EurJBiochem.
1997Jan15;243(1-2):518-526.
23.Zaharevitz DW,Gussio R,Leost M,Senderowicz AM,Lahusen T, Kunick C, Meijer L, Sausville EA. Discovery and initial characterization of the paullones,a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999 Jun 1;59(11):2566-2569.
24.Senderowicz AM.Small-molecule cyclin-dependentkinase modulators. Oncogene.2003Sep29;22(42):6609-6620.
25. Kim SA, Kim SW, Chang S, Yoon JH, Ahn SG.
5'-nitro-indirubinoxime induces G2/M cellcycle arrestand apoptosis inhumanKB oralcarcinomacells.CancerLett.2009Feb274(1):72-77. 26.RaucciA,Palumbo R,BianchiME.HMGB1:a signalofnecrosis.
Autoimmunity.2007Jun;40(4):285-289.
27. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002 Jul 11;418(6894):191-195.
28. Subramaniam D, Periyasamy G, Ponnurangam S, Chakrabarti D, SugumarA,Padigaru M,WeirSJ,Balakrishnan A,SharmaS,Anant S. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. Mol Cancer Ther. 2012 Jul;11(7):1598-1608.
29.Dickson MA,Schwartz GK.Developmentofcell-cycle inhibitors for cancertherapy.CurrOncol.2009Mar;16(2):36-43.
30.FuldaS,DebatinKM.Extrinsicversusintrinsicapoptosispathwaysin anticancerchemotherapy.Oncogene.2006Aug7;25(34):4798-4811.
31.AdamsJM,CoryS.TheBcl-2apoptoticswitchincancerdevelopment andtherapy.Oncogene.2007Feb26;26(9):1324-1337.
32.Kroemer G.The proto-oncogene Bcl-2 and its role in regulating apoptosis.NatMed.1997Jun;3(6):614-620.
33.AshkenaziA,DixitVM.Death receptors:signaling and modulation.
Science.1998Aug28;281(5381):1305-1308.
34.PorterAG,JänickeRU.Emerging rolesofcaspase-3in apoptosis.Cell DeathDiffer.1999Feb;6(2):99-104.
35.CarteeL,MaggioSC,SmithR,SankalaHM,DentP,GrantS.Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosisinhumanmyeloidleukemiacellsexposedtobryostatin1and flavopiridol.MolCancerTher.2003Jan;2(1):83-93.